Many viral proproteins must be processed in order to produce infectious progeny. In the case of HIV-1, the viral envelope proprotein gp160 must undergo proteolytic cleavage by cellular serine proteases to liberate its active peptide subfragments, gp120 and gp41. 1 In addition, HIV protease (PR) processes the HIV Gag and Gag-Pol polyproteins to release a large number of mature proteins that are obligatory for HIV viral particle assembly and maturation, and for virion progeny to be infectious. 2 Gene delivery to cultured human lymphocyte cell lines and primary human lymphocyte provides expression of native human a 1 -antitrypsin (a 1 AT), a serine protease inhibitor, 3 that these cells do not normally express. Thus supplied to these cells, a 1 AT strongly inhibits replication and spread of HIV by blocking two necessary steps in HIV proprotein processing: it blocks cellular serine proteases that process gp160 to gp120 and gp41, and decreases the activity of HIV PR, an aspartyl protease that cleaves p55 Gag within budding viral particles. The resulting a 1 AT expression strongly inhibits subsequent HIV challenge. 4 To deliver a 1 AT, we used SV(AT), a viral vector derived from Tag-deleted simian virus-40 (SV40). SV40 infects of wide range of cell types from humans and other mammals, ensuring expression of its genome. Recombinant, T-antigen-deleted, replication-deficient, SV40-derived vectors (rSV40) deliver stable transgene expression with high efficiency and without selection to cell lines and in primary cell cultures, and in vivo. [5] [6] [7] [8] In SV(AT), a 1 AT expression is driven by a constitutive promoter, the cytomegalovirus immediate-early promoter (CMV-IEP). 9 The broad and important role of cellular serine proteases in the proteolysis of proprotein substrates, including activation of many pathogen molecules and bacterial toxins has made endoproteases targets for the development of potent and selective inhibitors. [10] [11] [12] . However, to exploit these findings in devising HIV therapies, a conditional promoter that is HIV-specific, such as the HIV-1 LTR, should be used to drive expression of a 1 AT. In this study, SV[LTR](AT) was designed so that production of human a 1 AT would be trans-activated when a cell was infected with HIV-1 ( Figure 1) . Results presented here demonstrate that both T-cell lines and primary blood lymphocytes transduced with SV[LTR](AT) produced high levels of AT on exposure to HIV and were protected from HIV challenge similar to cells transduced with SV(AT).
SV [LTR] (AT), carrying the cDNA encoding human a 1 AT driven by HIV-1 NL4-3 LTR, was produced, packaged and titered as described previously. 13, 14 Control viruses for these studies have been reported: SV(HBS) 15 and SV(BUGT), 16 which respectively carry the cDNA for hepatitis B surface antigen (HBsAg) and human bilirubin-UDP-glucuronosyl-transferase.
The ability of SV[LTR](AT) to deliver expression of a 1 AT that was activated by HIV- We have recently reported that delivering a 1 AT to human lymphocyte cell lines or primary human lymphocytes using SV(AT) strongly inhibits HIV replication. The likely mechanism for this effect is in part direct inhibition of cellular serine proteases that process gp160, and of HIV-1 PR that cleaves p55 Gag1 . The need for cellular serine proteases is a cellular function that is unlikely to be circumvented by virus mutation and thus may be an important target for anti-HIV therapeutics. a 1 AT is generally considered to be relatively specific for a small group of serine proteases, including neutrophil elastase and furin; it does not affect the activities of many other serine proteases (eg chymotrypsin).
However, the wide variety of serine proteases and the large number of serine protease targets underscore the importance of using a conditional, HIV-responsive promoter to drive expression of a 1 AT to inhibit HIV replication. In this work, we exploited the ability of the conditional promoter HIV-1 LTR to drive a 1 AT expression in HIV-1-infected cells only. We have used this promoter efficiently to deliver conditional expression of other transgenes. Conditional expression of a 1 AT driven by HIV-1 LTR as a promoter was documented in cells expressing HIV-1 Tat and/or challenged with HIV-1. We observed that delivery of a 1 AT to cell lines inhibited HIV replication, at challenge doses that normally produce a large amount of p24 antigen and extensive cell death. Conditional expression of a 1 AT driven by HIV-1 LTR provided protection as good as that provided by a construct in which a 1 AT expression was driven by CMV-IEP. Use of the HIV LTR as a promoter is thus an efficient way of selectively expressing therapeutic genes in target cells in response to HIV challenge. Since a 1 AT impedes a late (postintegration) function in HIV replicative cycle, its Conditional expression of a 1 -antitrypsin inhibits HIV-1 replication dependence on the HIV LTR as a promoter allows a high level of effectiveness and specificity.
The ability of SV40 to transduce nonproliferating PBL is essential in gene therapy for HIV infection, since nonactivated T-lymphocytes are important cellular reservoirs for HIV-1, in vivo. In the current study, we demonstrated that SV[LTR](AT) treatment of unstimulated primary human lymphoid cells can protect from HIV challenge. The combination of this highly efficient gene delivery vector with an effective anti-HIV therapeutic gene is currently being tested for efficacy in SCID-hu mice challenged with HIV, in vivo. Conditional expression of a 1 -antitrypsin inhibits HIV-1 replication P Cordelier and DS Strayer
